Drug Trial Radar · NCT03532542
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
171
Actual
Start
Aug 2, 2018
Primary completion
Jul 26, 2023
Study completion Jul 26, 2023
Sponsor
- Lead sponsor
- Sarepta Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 22, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 7 years, up to 23 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).
Conditions
- Duchenne Muscular Dystrophy
Interventions
CasimersenDrug
Casimersen solution for IV infusion
GolodirsenDrug
Golodirsen solution for IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)Time frame: Up to 33 days after the last infusion of study drug (up to approximately 149 weeks)
Locations
50 sites in 13 countries. Site status is shown where the registry gives one.
Neuromuscular Research Center
Phoenix, Arizona
Children's Hospital Los Angeles
Los Angeles, California
University of California Los Angeles
Los Angeles, California
Stanford Neuroscience Health Center
Palo Alto, California
Rady Children's Hospital- San Diego
San Diego, California
UF Health: University of Florida Clinical Research Center
Gainesville, Florida
NW Florida Clinical Research Group, LLC
Gulf Breeze, Florida
Rare Disease Research, LLC
Atlanta, Georgia
Ann and Robert H Lurie Childrens Hospital of Chicago
Chicago, Illinois
University of Iowa Childrens Hospital
Iowa City, Iowa
University of Kansas Medical Center
Kansas City, Kansas
Kennedy Krieger Institute
Baltimore, Maryland
Boston Children's Hospital
Boston, Massachusetts
St. Louis Children's Hospital
St Louis, Missouri
Las Vegas Clinic
Las Vegas, Nevada
University of Rochester Medical Center - Department of Neurology
Rochester, New York
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Abigail Wexner Research Institute at Nationwide Children's Hospital
Columbus, Ohio
Shriners Hospital for Children
Portland, Oregon
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania
Children's Medical Center Dallas
Dallas, Texas
Texas Children's Hospital
Houston, Texas
University of Utah - PPDS
Salt Lake City, Utah
Children's Hospital of The King's Daughters
Norfolk, Virginia
Children's Hospital of Wisconsin, Corporate Center Suite 540
Milwaukee, Wisconsin
UZ Leuven
Leuven, Belgium
UZ Gent
Ghent, Oost-Vlaanderen, Belgium
University Multiprofile Hospital for active treatment Aleksandrovska EAD Clinic of Neurological Diseases
Sofia, Bulgaria
Alberta Children's Hospital
Calgary, Alberta, Canada
Children's Hospital of Eastern Ontario
Ottawa, Ontario, Canada
Fakultni nemocnice Brno, Klinika detske neurologie LF MU a FN Brno
Brno, Czechia
Fakultni nemocnice v Motole
Prague, Czechia
Hotel Dieu- CHU Nantes
Nantes, France
Hôpital Armand Trousseau
Paris, France
Universitatsklinikum Freiberg
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Universitatsklinikum Essen
Essen, North Rhine-Westphalia, Germany
Schneider Children's Medical Center of Israel
Petah Tikva, Israel
Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant' Anna
Cona, Italy
Fondazione Policlinico Universitario A Gemelli
Milan, Italy
UOSD Centro Traslazionale di Miologia e Patologie Neurogenerative
Genoa, Liguria, Italy
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.